The Experts below are selected from a list of 579 Experts worldwide ranked by ideXlab platform
Reinoud Gosens - One of the best experts on this subject based on the ideXlab platform.
-
Airway Smooth Muscle phenotype and function: interactions with current asthma therapies.
Current drug targets, 2006Co-Authors: Andrew J. Halayko, Thai Tran, Akira Yamasaki, Reinoud GosensAbstract:Asthma incidence has climbed markedly in the past two decades despite an increased use of medications that suppress airway inflammation and repress contraction of Smooth Muscle that encircles the airways. Asthmatics exhibit episodes of airway inflammation that potentiates reversible airway Smooth Muscle Spasm. A hallmark diagnostic symptom of asthma is airway hyperresponsiveness to inhaled non-allergic stimuli, such as methacholine, that directly induce airway Smooth Muscle contraction. Inhaled gluccocorticoids are used for first-line prevention of airway inflammation, and are frequently combined with inhaled beta2-adrenoceptor agonists that can effectively relax airway Smooth Muscle and restore airway conductance. Leukotriene receptor antagonists and anti-cholinergics can also be used in many patients to ensure optimal control of symptoms. With increasing disease duration irreversible airway restriction develops from inflammation-driven fibro-proliferative airway remodeling that includes increased deposition of extracellular matrix, the accumulation of airway Smooth Muscle, and increased numbers of myofibroblasts. Mature airway Smooth Muscle cells are phenotypically plastic, enabling them to subserve contractile, proliferative, migratory and secretory functional responses that contribute to airway remodeling and persistent hyperresponsiveness. This review assesses current understanding of acute and chronic effects of common anti-asthma medications on the diverse phenotype and functional characteristics of airway Smooth Muscle cells. Furthermore, we describe the significance of these effects in the treatment of asthma symptoms and pathogenesis.
Andrew J. Halayko - One of the best experts on this subject based on the ideXlab platform.
-
Airway Smooth Muscle phenotype and function: interactions with current asthma therapies.
Current drug targets, 2006Co-Authors: Andrew J. Halayko, Thai Tran, Akira Yamasaki, Reinoud GosensAbstract:Asthma incidence has climbed markedly in the past two decades despite an increased use of medications that suppress airway inflammation and repress contraction of Smooth Muscle that encircles the airways. Asthmatics exhibit episodes of airway inflammation that potentiates reversible airway Smooth Muscle Spasm. A hallmark diagnostic symptom of asthma is airway hyperresponsiveness to inhaled non-allergic stimuli, such as methacholine, that directly induce airway Smooth Muscle contraction. Inhaled gluccocorticoids are used for first-line prevention of airway inflammation, and are frequently combined with inhaled beta2-adrenoceptor agonists that can effectively relax airway Smooth Muscle and restore airway conductance. Leukotriene receptor antagonists and anti-cholinergics can also be used in many patients to ensure optimal control of symptoms. With increasing disease duration irreversible airway restriction develops from inflammation-driven fibro-proliferative airway remodeling that includes increased deposition of extracellular matrix, the accumulation of airway Smooth Muscle, and increased numbers of myofibroblasts. Mature airway Smooth Muscle cells are phenotypically plastic, enabling them to subserve contractile, proliferative, migratory and secretory functional responses that contribute to airway remodeling and persistent hyperresponsiveness. This review assesses current understanding of acute and chronic effects of common anti-asthma medications on the diverse phenotype and functional characteristics of airway Smooth Muscle cells. Furthermore, we describe the significance of these effects in the treatment of asthma symptoms and pathogenesis.
Andreas F. Widmer - One of the best experts on this subject based on the ideXlab platform.
-
Microbial colonization and ureteral stent-associated storage lower urinary tract symptoms: the forgotten piece of the puzzle?
World Journal of Urology, 2013Co-Authors: Gernot Bonkat, Malte Rieken, Georg Müller, Alexander Roosen, Reno Frei, Stephen Wyler, Alexander Bachmann, Fabian P. Siegel, Thomas Gasser, Andreas F. WidmerAbstract:Purpose Ureteral stents are frequently associated with side effects. Most patients suffer from storage lower urinary tract symptoms (LUTS). Storage LUTS are commonly attributed to the irritation of the trigone, Smooth Muscle Spasm or a combination of factors. The relationship between microbial ureteral stent colonization (MUSC) and de novo or worsening storage LUTS has not been investigated yet. Methods Five hundred ninety-one polyurethane ureteral stents from 275 male and 153 female patients were prospectively evaluated. The removed stents were sonicated to dislodge adherent microorganisms. Urine flow cytometry was performed to detect pyuria. A standardized urinary symptom questionnaire was given to all patients. Results Thirty-five per cent of male and 28% of female cases showed de novo or worsened storage LUTS. MUSC was more common in patients with storage LUTS compared to patients without storage LUTS (men: 26 vs. 13%, respectively, P
Akira Yamasaki - One of the best experts on this subject based on the ideXlab platform.
-
Airway Smooth Muscle phenotype and function: interactions with current asthma therapies.
Current drug targets, 2006Co-Authors: Andrew J. Halayko, Thai Tran, Akira Yamasaki, Reinoud GosensAbstract:Asthma incidence has climbed markedly in the past two decades despite an increased use of medications that suppress airway inflammation and repress contraction of Smooth Muscle that encircles the airways. Asthmatics exhibit episodes of airway inflammation that potentiates reversible airway Smooth Muscle Spasm. A hallmark diagnostic symptom of asthma is airway hyperresponsiveness to inhaled non-allergic stimuli, such as methacholine, that directly induce airway Smooth Muscle contraction. Inhaled gluccocorticoids are used for first-line prevention of airway inflammation, and are frequently combined with inhaled beta2-adrenoceptor agonists that can effectively relax airway Smooth Muscle and restore airway conductance. Leukotriene receptor antagonists and anti-cholinergics can also be used in many patients to ensure optimal control of symptoms. With increasing disease duration irreversible airway restriction develops from inflammation-driven fibro-proliferative airway remodeling that includes increased deposition of extracellular matrix, the accumulation of airway Smooth Muscle, and increased numbers of myofibroblasts. Mature airway Smooth Muscle cells are phenotypically plastic, enabling them to subserve contractile, proliferative, migratory and secretory functional responses that contribute to airway remodeling and persistent hyperresponsiveness. This review assesses current understanding of acute and chronic effects of common anti-asthma medications on the diverse phenotype and functional characteristics of airway Smooth Muscle cells. Furthermore, we describe the significance of these effects in the treatment of asthma symptoms and pathogenesis.
Thai Tran - One of the best experts on this subject based on the ideXlab platform.
-
Airway Smooth Muscle phenotype and function: interactions with current asthma therapies.
Current drug targets, 2006Co-Authors: Andrew J. Halayko, Thai Tran, Akira Yamasaki, Reinoud GosensAbstract:Asthma incidence has climbed markedly in the past two decades despite an increased use of medications that suppress airway inflammation and repress contraction of Smooth Muscle that encircles the airways. Asthmatics exhibit episodes of airway inflammation that potentiates reversible airway Smooth Muscle Spasm. A hallmark diagnostic symptom of asthma is airway hyperresponsiveness to inhaled non-allergic stimuli, such as methacholine, that directly induce airway Smooth Muscle contraction. Inhaled gluccocorticoids are used for first-line prevention of airway inflammation, and are frequently combined with inhaled beta2-adrenoceptor agonists that can effectively relax airway Smooth Muscle and restore airway conductance. Leukotriene receptor antagonists and anti-cholinergics can also be used in many patients to ensure optimal control of symptoms. With increasing disease duration irreversible airway restriction develops from inflammation-driven fibro-proliferative airway remodeling that includes increased deposition of extracellular matrix, the accumulation of airway Smooth Muscle, and increased numbers of myofibroblasts. Mature airway Smooth Muscle cells are phenotypically plastic, enabling them to subserve contractile, proliferative, migratory and secretory functional responses that contribute to airway remodeling and persistent hyperresponsiveness. This review assesses current understanding of acute and chronic effects of common anti-asthma medications on the diverse phenotype and functional characteristics of airway Smooth Muscle cells. Furthermore, we describe the significance of these effects in the treatment of asthma symptoms and pathogenesis.